Leimin Sun

Dr. Leimin Sun

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
YLYue Li
Yue Li
XHXingkang He
Xingkang He
YDYu’e Ding
Yu’e Ding
HCHongyang Chen
Hongyang Chen
LSLeimin Sun
Leimin Sun
Background: Colorectal cancer (CRC) remains one of the most common types of cancer and a leading cause of death worldwide. Previous studies indicated that statins may have a potential protective effect on CRC.Methods: We conducted this meta‐analysis to systematically assess the overall and cancer‐specific survival benefit of statin uses on CRC patients. Related references were identified through PubMed, the Cochrane Library, Web of Science, EMBASE, and SCOPUS from inception to August 2017. Adjusted hazard ratios (HRs) were adopted to calculate summary hazard ratios (HRs) with 95% confidence intervals (95% CIs), using a random‐effects model.Results: Total fourteen studies involving 130 994 patients were included in this meta‐analysis. Six studies reported the association between pre‐diagnosis statin uses and CRC mortality, while 11 studies investigated mortality in patients using statins after CRC diagnosis. For pre‐diagnosis statin uses, the pooled HR of all‐cause mortality (ACM) was 0.85 (95% CI, 0.79‐0.92) and the pooled HR of cancer‐specific mortality (CSM) was 0.82 (95% CI, 0.79‐0.86). In terms of post‐diagnosis statin uses, the pooled HR of ACM was 0.86 (95% CI, 0.76‐0.98), and the pooled HR of CSM was 0.79 (95% CI, 0.70‐0.89). For post‐diagnosis statin uses, there is no difference in ACM when stratified by KRAS gene (KRAS) mutation status. Results of ACM and CSM did not markedly alter in other subgroup analyses.Conclusion: Our meta‐analysis demonstrates that both pre‐diagnosis and post‐diagnosis statin uses are associated with reduced ACM and CSM for CRC patients.

20 October 2017 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
XHXingkang He
Xingkang He
WWWenrui Wu
Wenrui Wu
ZLZhenghua Lin
Zhenghua Lin
YDYue Ding
Yue Ding
JSJianmin Si
Jianmin Si
LSLeimin Sun
Leimin Sun

13 March 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XHXingkang He
Xingkang He
WWWenrui Wu
Wenrui Wu
YDYu'E Ding
Yu'E Ding
YLYue Li
Yue Li
JSJianmin Si
Jianmin Si
LSLeimin Sun
Leimin Sun
With an increasing trend of patients with young‐onset colorectal cancer (CRC), risks of second primary cancers (SPCs) among them become a concerning issue. We aimed to define the detailed risk and site‐distributed patterns of SPCs in young CRC individuals (age ≤50). A population‐based cohort were identified from the Surveillance, Epidemiology, and End Results database between 1973 and 2013. Standardized incidence ratios (SIRs) and absolute excess risk (AER) were calculated to assess the risk for SPCs compared with the general population. A total of 44,106 patients, including 3245 (7.4%) the young and 40,861 (92.6%) the old, developed 50,679 secondary malignancies subsequently. With increased age, the risk of secondary cancers gradually decreased. A significant 44% excess risk of SPCs was observed in the young (SIR = 1.44, AER = 34.23), while a slightly increased risk was noted in the old (SIR = 1.02, AER = 4.29). For young survivors, the small intestine (SIR = 8.49), bile ducts (SIR = 3.77), corpus, and uterus (SIR = 2.45) were the most common sites of SPCs. Significantly, excess SIRs in the young were persisted regardless of other factors. For the young, secondary cancer‐related deaths were responsible for 51.2% of overall deaths and secondary stomach, liver and bile, pancreas cancers were top three causes. An excessive risk of SPCs existed in young CRC survivors, and this trend was consistent among different subgroups. We hope our findings may inform future targeted screening strategies among young‐onset CRC survivors.

6 March 2019 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
SMSibin Mei
Sibin Mei
MWMengyu Wang
Mengyu Wang
LSLeimin Sun
Leimin Sun
Background. Though methods for the diagnosis of pancreatic masses are various, such as ultrasonography (US), computed tomography (CT), endoscopic ultrasonography (EUS), and contrast-enhanced computed tomography (CE-CT), their sensitivity, specificity, and accuracy are not quite satisfying. Contrast-enhanced endoscopic ultrasonography (CE-EUS), as a new technique, has its own unique advantages in diagnosing pancreatic disease. However, its sensitivity, specificity, and accuracy are still controversial. Objective. To evaluate the accuracy of CE-EUS for differential diagnosis between benign and malignant pancreatic mass lesions. Design. Eighteen relevant articles systemically searched from PubMed, Web of Science, Ovid, Scopus, and MEDLINE were selected. The pooled results were calculated in a fixed effects model. Main Outcome Measurement. The pooled sensitivity, specificity, positive likelihood ratio (LR), negative likelihood ratio, diagnostic odds ratio (OR), and summary receiver operating characteristic (SROC) curve. Results. The pooled sensitivity, specificity, and diagnostic odds ratio of CE-EUS for the differential diagnosis of pancreatic adenocarcinomas were 0.91 (95% confidence interval (CI), 0.89-0.93), 0.86 (95% CI, 0.83-0.89), and 69.50 (95% CI, 48.89-98.80), respectively. The SROC area under the curve was 0.9545. The subgroup analysis based on excluding the outliers showed that the heterogeneity was eliminated and the pooled sensitivity and specificity were 0.92 (95% CI, 0.90-0.93) and 0.87 (95% CI, 0.84-0.89), respectively. The SROC area under the curve was 0.9569. Conclusion. CE-EUS is a useful method to distinguish pancreatic adenocarcinoma from other pancreatic diseases. Compared with EUS elastography, it has higher specificity. However, it is still not superior to pathological diagnosis for the identification of pancreatic carcinomas.

3 December 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
YLYiming Liu
Yiming Liu
YWYue Wang
Yue Wang
JZJiaying Zhou
Jiaying Zhou
HLHong Li
Hong Li
CLCaiyun Liu
Caiyun Liu
LSLeimin Sun
Leimin Sun
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex and heterogeneous metabolic disorder where subcellular organelle dysfunction and disrupted inter-organelle communication are recognized as increasingly important drivers of pathogenesis, moving beyond traditional views focused solely on macroscopic metabolic regulation. This review systematically explores the functional impairments of key organelles—including mitochondria, the endoplasmic reticulum, lipid droplets, and autophagic pathways—to delineate their collective roles in fostering lipid metabolism imbalance, oxidative stress, and inflammation. A key innovation discussed is how the pathological dysregulation of membrane contact sites (MCSs) acts as a pivotal mechanism decoupling organelle function and accelerating disease progression. We conclude that therapeutic strategies aimed at restoring cellular metabolic flexibility—by precisely modulating MCSs, activating clearance pathways, and restoring energy metabolism—represent a promising new paradigm for treating MASLD, particularly in patient populations unresponsive to current therapies.

1 January 2018 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
XHXingkang He
Xingkang He
WZWenfang Zheng
Wenfang Zheng
YDYue Ding
Yue Ding
XTXia Tang
Xia Tang
JSJianmin Si
Jianmin Si
LSLeimin Sun
Leimin Sun
Background and Aim. Rectal indomethacin was reported to be effective for postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) prophylaxis. However, the preventive effect of indomethacin for average-risk patients remains unclear. Recently, some conflicting evidence was addressed by recent articles. We aimed to determine the protective role of indomethacin in PEP based on the latest available literature. Methods. A systematic literature search was conducted using PubMed, Embase, Web of Science, and the Cochrane Library to identify related articles published before October 2016. Studies that evaluated the administration of indomethacin in the prevention of PEP were included in the analysis. We adopted a random-effects model to calculate the overall relative risk (RR) and 95% confidence interval (CI). Results. Ten trials from an initial search were finally included in the meta-analysis. The administration of rectal indomethacin significantly reduced the incidence of PEP in consecutive ERCP population (RR, 0.63; 95% CI, 0.50–0.77). There was no significant heterogeneity across included studies (I2=14.2%, P=0.31). Further subgroup analyses also revealed that rectal indomethacin could protect the individuals at high and average risks and reduced severity of PEP. Pre-ERCP administration of indomethacin seemed to be better than the post-ERCP given. There was no evidence of significant publication bias. Conclusions. Rectal administration of indomethacin is an effective approach to prevent the incidence of PEP in both high- and average-risk populations undergoing ERCP. However, more high-quality RCTs are needed to further investigate the optimal timing for the administration of indomethacin.